BACKGROUND:Pregabalin is a calcium channel α2δ ligand that modifies visceral hypersensitivity in IBS patients. Clinical data for pregabalin in IBS are lacking. AIM: To test the efficacy of pregabalin on gastrointestinal symptoms in IBS patients. METHODS: A double-blind, placebo-controlled trial was performed. Adults meeting IBS Rome III criteria with ≥3 pain attacks per month were randomised to pregabalin 225 mg vs placebo twice daily for 12 weeks. Questionnaires were completed weekly. The primary endpoint was average painBowel Symptom Scale (BSS) scores weeks 9-12. An intention-to-treat analysis of covariance evaluated treatment effects on quantitative endpoints, adjusting for age and gender. Adequate relief and change in pain score were assessed using a chi-squared test. RESULTS:Eighty-five patients were recruited and randomised. Sample characteristics include: mean age 39.4 (SD = 14.6); 73 (86%) female; 37 (44%) IBS-D, 29 (35%) IBS-M, 18 (21%) IBS-C. The pregabalin arm had lower average pain-BSS scores weeks 9-12 (25 vs 42, P = 0.008). Compared with placebo, the overall IBS BSS severity score was lower in the pregabalin arm (26 vs 42, P = 0.009). Differences were observed for the diarrhoea-BSS and bloating-BSS scores (P = 0.049 and 0.016, respectively). No differences between groups were seen for constipation-BSS scores. Adequate relief was not different between the two arms (46% vs 36%, P = 0.35). 63% pregabalin vs 45% placebo had a change in pain score≥30 at week 12 from baseline (P = 0.10). Post-treatment IBS-QoL scores did not differ between groups. CONCLUSION: This trial suggests that pregabalin may be beneficial for IBS abdominal pain, bloating and diarrhoea.
RCT Entities:
BACKGROUND:Pregabalin is a calcium channel α2δ ligand that modifies visceral hypersensitivity in IBSpatients. Clinical data for pregabalin in IBS are lacking. AIM: To test the efficacy of pregabalin on gastrointestinal symptoms in IBSpatients. METHODS: A double-blind, placebo-controlled trial was performed. Adults meeting IBS Rome III criteria with ≥3 pain attacks per month were randomised to pregabalin 225 mg vs placebo twice daily for 12 weeks. Questionnaires were completed weekly. The primary endpoint was average pain Bowel Symptom Scale (BSS) scores weeks 9-12. An intention-to-treat analysis of covariance evaluated treatment effects on quantitative endpoints, adjusting for age and gender. Adequate relief and change in pain score were assessed using a chi-squared test. RESULTS: Eighty-five patients were recruited and randomised. Sample characteristics include: mean age 39.4 (SD = 14.6); 73 (86%) female; 37 (44%) IBS-D, 29 (35%) IBS-M, 18 (21%) IBS-C. The pregabalin arm had lower average pain-BSS scores weeks 9-12 (25 vs 42, P = 0.008). Compared with placebo, the overall IBS BSS severity score was lower in the pregabalin arm (26 vs 42, P = 0.009). Differences were observed for the diarrhoea-BSS and bloating-BSS scores (P = 0.049 and 0.016, respectively). No differences between groups were seen for constipation-BSS scores. Adequate relief was not different between the two arms (46% vs 36%, P = 0.35). 63% pregabalin vs 45% placebo had a change in pain score ≥30 at week 12 from baseline (P = 0.10). Post-treatment IBS-QoL scores did not differ between groups. CONCLUSION: This trial suggests that pregabalin may be beneficial for IBS abdominal pain, bloating and diarrhoea.
Authors: Alexander C Ford; Paul Moayyedi; Brian E Lacy; Anthony J Lembo; Yuri A Saito; Lawrence R Schiller; Edy E Soffer; Brennan M R Spiegel; Eamonn M M Quigley Journal: Am J Gastroenterol Date: 2014-08 Impact factor: 10.864
Authors: Anthony J Lembo; Brian E Lacy; Marc J Zuckerman; Ron Schey; Leonard S Dove; David A Andrae; J Michael Davenport; Gail McIntyre; Rocio Lopez; Lisa Turner; Paul S Covington Journal: N Engl J Med Date: 2016-01-21 Impact factor: 91.245
Authors: D A Drossman; Z Li; E Andruzzi; R D Temple; N J Talley; W G Thompson; W E Whitehead; J Janssens; P Funch-Jensen; E Corazziari Journal: Dig Dis Sci Date: 1993-09 Impact factor: 3.199
Authors: Péter Varjú; Nelli Farkas; Péter Hegyi; András Garami; Imre Szabó; Anita Illés; Margit Solymár; Áron Vincze; Márta Balaskó; Gabriella Pár; Judit Bajor; Ákos Szűcs; Orsolya Huszár; Dániel Pécsi; József Czimmer Journal: PLoS One Date: 2017-08-14 Impact factor: 3.240
Authors: L Chang; W D Chey; D Drossman; T Losch-Beridon; M Wang; P Lichtlen; S Mareya Journal: Aliment Pharmacol Ther Date: 2016-09-27 Impact factor: 8.171
Authors: Asbjørn M Drewes; Anne E Olesen; Adam D Farmer; Eva Szigethy; Vinciane Rebours; Søren S Olesen Journal: Nat Rev Dis Primers Date: 2020-01-06 Impact factor: 52.329
Authors: Lili Zhou; Sandipan Bhattacharjee; C Kent Kwoh; Patrick J Tighe; Gary M Reisfield; Daniel C Malone; Marion Slack; Debbie L Wilson; Ching-Yuan Chang; Wei-Hsuan Lo-Ciganic Journal: Addiction Date: 2020-08-19 Impact factor: 6.526